CClinicalTrials.gg
Sign In
RecruitingNCT06780475VIRASKINUpdated Nov 19, 2025

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

An observational study in Merkel Cell Carcinoma of Skin, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

From the registry’s dates

  • Started May 2025; still recruiting 1 year 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Read the detailed description

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

02

Conditions studied

  • Merkel Cell Carcinoma of Skin

Keywords

  • Merkel Cell Carcinoma of Skin
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients of Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or with an active follow-up beside dermatologist.

Inclusion criteria

  • Patients >= 18 years old;
  • Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
  • Informed for the study and no-opposed for participation;
  • Affiliated with a social security scheme or in an equivalent situation.

Exclusion criteria

Exclusion Criteria:

  • Patients ongoing another interventional clinical trial;
  • Patients under guardianship or trusteeship;
  • Pregnancy or breastfeed;
  • Patients refusal.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Anti-MCPyV functionality

    Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.

    Time frame: Day 0 and Day 4

07

Study locations

1 of 1 sites recruiting
  • Dermato-oncology Department, Ambroise Paré Hospital, APHP
    Boulogne-Billancourt, 92100, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06780475
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
May 27, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 19, 2025

Study contacts

Astrid Blom, MD
Contact
astrid.blom@aphp.fr
+33 (01) 49 09 44 82
Yassine Taoufik, MD, PhD
Contact
yassine.taoufik@aphp.fr
Astrid Blom, MD
principal investigator · Dermato-oncology Department, Ambroise Paré Hospital, APHP
Yassine Taoufik, MD, PhD
study director · U1186 INSERM, PAUL BROUSSE Hospital, APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Assistance Publique - Hôpitaux de Paris

Start the discussion